SELLAS Life Sciences Group, Inc. (SLS)

Many, many, catalysts in place for SLS including a new cancer treatment drug, co-developed by MERCK, now entering phase III FDA testing.
Additional round of S-1 financing was completed in under FOUR days! Meaning some entity(s) really really wanted to scoop up as much SLS as possible... quite possibly MERCK.

08/05/19 SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast

 

As you can see, the recent low was established on July 1st at .1021.
Then a nearly 200% gain sent the PPS soaring up to .2880.
This was followed by a smooth decline where it bottomed out at .1200.
And earlier this week it rose (once again, the change was nice & smooth) to .2489.
These changes formed the cup.

Now the PPS has leveled out at a new bottom of roughly .1600, which is up from the recent low as well as the low point in the cup.
Together, you have a textbook Cup and Handle chart.
The next run should be significantly higher than the high of the cup's lips, which was .2880
Additional indicators show that a reversal back up in taking place.